A Multicenter, Randomized, Double-Blind, Active-Parallel-Controlled, Phase 3 Clinical Study to Investigate the Efficacy and Safety of DWP14012 in the Treatment of Reflux Esophagitis
Latest Information Update: 23 Aug 2024
At a glance
- Drugs Fexuprazan (Primary) ; Esomeprazole; Lansoprazole
- Indications Reflux oesophagitis
- Focus Registrational; Therapeutic Use
- Sponsors Daewoong Pharmaceutical
Most Recent Events
- 31 Jul 2023 According to a Daewoong Pharmaceuticals, company has submitted the New Drug Application (NDA) for Fexuprazan to the Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA), based on the results of Phase 3 clinical trials for GERD treatment conducted on 332 patients with erosive esophagitis in China.
- 19 May 2023 Results of this study presented at the Digestive Disease Week 2023 (DDW 2023) held in Chicago, USA.
- 19 May 2023 Results presented in a Daewoong Pharmaceutical Media Release.